- Home
- PDM vs ALVO Comparison
PDM vs ALVO Comparison
Compare PDM & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | ALVO |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDM | ALVO |
|---|---|---|
| Price | $8.23 | $3.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $9.00 | $8.00 |
| AVG Volume (30 Days) | ★ 1.2M | 333.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,994,000.00 | N/A |
| Revenue This Year | $4.21 | $13.28 |
| Revenue Next Year | $1.29 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $3.03 |
| 52 Week High | $9.19 | $11.85 |
Technical Indicators
Market Signals| Indicator | PDM | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 50.58 |
| Support Level | $8.03 | $3.03 |
| Resistance Level | $8.89 | $3.93 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 81.51 | 55.65 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.